Exploration of microstructure, mechanical, and corrosion properties in selective laser melting TiN/AISI 420 composites with diverse TiN reinforcement particle sizes

Đức Hoàn Trần

doi:10.1007/s10853-024-10525-7

Novel Risk Scoring System for Patients with Metastatic Castration Resistant Prostate Cancer Treated with Lutetium-177–PSMA-617

2026-07-11

0

OA

AI

M

Margo B Gerke, MD

A

Angelo Marra, MPH

M

Michelle Jayaraj, BA

A

Ahmet Yildrim, MD

A

Akshay Bedmutha, MD

J

Jacqueline T Brown, MD

B

Bassel Nazha, MD

J

Jacob E Berchuck, MD

R

Ravi Bharat Parikh, MD

S

Shahid Ahmed, MD

J

Jordan Alana Ciuro, MD

C

Caitlin Hartman, FNP

G

Greta Russler McClintock, FNP

S

Sarah Caulfield, PharmD

O

Omer Kucuk, MD

B

Bradley Curtis Carthon, MD, PhD

D

David M Schuster, MD

S

Saima Muzahir, MD

Y

Yuan Liu, PhD

M

Mehmet Asim Bilen, MD *

DOI：10.1093/oncolo/oyag269

Original

Original request for help

Save

Abstract

En 中文

Lutetium-177(177Lu)–PSMA-617 improves survival for patients with metastatic castration-resistant prostate cancer (mCRPC), but outcomes are heterogeneous and standardized risk stratification tools are lacking. We developed a novel risk stratification tool for patients treated with 177Lu–PSMA-617.

Novel Risk Scoring System for Patients with Metastatic Castration Resistant Prostate Cancer Treated with Lutetium-177–PSMA-617

Abstract

Journal

Organization

Cited Papers

Citing Papers